Neoadjuvant use of oncolytic herpes virus G47Δ prevents local recurrence after insufficient resection in tongue cancer models. Neoadjuvant use of oncolytic herpes virus G47Δ prevents local recurrence after insufficient resection in tongue cancer models

Mice with orthotopic tongue cancer received neoadjuvant G47Δ therapy. Neoadjuvant G47Δ and resection led to 10/10 survival even with insufficient resection margins. Overall design: Comparative gene expression profiling analysis of RNA-seq data for murine tongue tumors after intratumoral inoculation of G47Δ.